Kristian Beran

Mr. Kristian Beran


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
KBKristian Beran
Kristian Beran
EHEline Hermans
Eline Hermans
René HolmRené Holm
René Holm
KSKia Sepassi
Kia Sepassi
JDJennifer Dressman
Jennifer Dressman
Supersaturation and precipitation within the gastrointestinal tract can influence oral absorption of active pharmaceutical ingredients (APIs). Supersaturation of weakly basic APIs upon transfer from the stomach into the small intestine may enhance their absorption, while salt forms of poorly soluble weak acids may generate supersaturated solutions in both stomach and intestine. Likewise, APIs with solubility-limited absorption may be developed as enabling formulations intended to produce supersaturated solutions of the API in the gut. Integrating the supersaturation/precipitation characteristics of the API into the biopharmaceutical risk classification enables comprehensive mapping of potential developability risks and guides formulation selection towards optimizing oral bioavailability (BA). The refined Developability Classification System (rDCS) provided an approach for this purpose. In this work, the rDCS strategy is revisited and a stratified approach integrating the in vitro supersaturation and precipitation behavior of APIs and their formulations is proposed.

8 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KBKristian Beran
Kristian Beran
EHEline Hermans
Eline Hermans
René HolmRené Holm
René Holm
KSKia Sepassi
Kia Sepassi
JDJennifer Dressman
Jennifer Dressman
Dissolution limitations to oral absorption can occur if the time required for dissolution is longer than the transit time across the small intestine and/or if dissolution is slower than the drug’s permeation through the gut wall. These limitations most often occur for poorly soluble drugs. A standard method for overcoming dissolution issues is to reduce the particle size of the (solid) drug. Building on the refined Developability Classification System (rDCS), this work establishes a novel set of equations with which the appropriate degree of particle size reduction needed to mitigate dissolution limitations to absorption can be calculated. According to the type of data available, the appropriate equation(s) for each situation can be applied. Three case examples are used to illustrate implementation of the equations: voriconazole, lemborexant and istradefylline. Although for voriconazole (rDCS Class I) target radius (rtarget) estimates indicate that particle size reduction is unnecessary, for lemborexant (rDCS Class I) a radius of ≤20 µm would be required to improve absorption. For istradefylline (rDCS Class IIb) the rtarget was approximately 12 µm. Results are commensurate with literature information for these three drugs, signaling that the equations are suitable for application to a wide variety of drug substances.

14 November 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KBKristian Beran
Kristian Beran
BABertil Abrahamsson
Bertil Abrahamsson
NCNaseem Charoo
Naseem Charoo
RCRodrigo Cristofoletti
Rodrigo Cristofoletti
René HolmRené Holm
René Holm
JDJennifer Dressman
Jennifer Dressman

5 October 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
KBKristian Beran
Kristian Beran
EHEline Hermans
Eline Hermans
René HolmRené Holm
René Holm
KSKia Sepassi
Kia Sepassi
JDJennifer Dressman
Jennifer Dressman
The refined Developability Classification System (rDCS) provides a comprehensive animal-free approach for assessing biopharmaceutical risks associated with developing oral formulations. This work demonstrates practical application of a recently advanced rDCS framework guiding formulation design for six diverse active pharmaceutical ingredients (APIs) and compares rDCS classifications with those of the Biopharmaceutics Classification System (BCS). While the BCS assigns five of the APIs to class II/IV, indicating potentially unfavorable biopharmaceutical attributes, the rDCS provides a more nuanced risk assessment. Both BCS and rDCS assign acetaminophen to class I at therapeutic doses. Voriconazole and lemborexant (both BCS II) are classified in rDCS class I at therapeutic doses, indicating suitability for development as conventional oral formulations. Fedratinib is classified as BCS IV but the rDCS indicates a stratified risk (class I, IIa or IIb), depending on the relevance of supersaturation/precipitation in vivo. Voxelotor and istradefylline (both BCS II) belong to rDCS class IIb, requiring solubility enhancement to achieve adequate oral bioavailability. Comparing the rDCS analysis with literature on development and pharmacokinetics demonstrates that the rDCS reliably supports oral formulation design over a wide range of API characteristics, thus providing a strong foundation for guiding development.

7 September 2025 in Molecular Pharmaceutics
Verified
Journal Article
Open access
KBKristian Beran
Kristian Beran
SPSeong Hee Park
Seong Hee Park
ABAn Van Den Bergh
An Van Den Bergh
JDJennifer Dressman
Jennifer Dressman
EHEline Hermans
Eline Hermans
RERaymond Evers
Raymond Evers
Human intestinal permeability is a key determinant of the oral fraction absorbed (fa) of active pharmaceutical ingredients (APIs). This study evaluated the ability of an in-house canine Mdr1 (cMdr1) knockout (KO) Madin-Darby Canine Kidney (MDCK) cell line to correlate in vitro apparent permeability (Papp) with human small intestinal permeability (Peff). In vitro Papp values of 16 reference compounds with high, medium, or low permeabilities were measured in the in-house cMdr1 KO MDCK protocol under pH gradient (6.5 ⇒ 7.4) and pH equivalent conditions (7.4 ⇒ 7.4) and correlations with human Peff were established (R2 > 0.8). The correlations were subsequently used to estimate Peff and fa for six test APIs: acetaminophen, voriconazole, fedratinib, voxelotor, lemborexant, and istradefylline. The results for these APIs were compared against literature and permeability data from other methods routinely used in drug discovery and development. The projected Peff and fa values for the test APIs aligned well with literature permeabilities derived using other methods and clinical pharmacokinetic studies, respectively. This work highlights the usefulness of cMdr1 KO MDCK cells in permeability classification, especially for highly permeable APIs, and supports its broader use in both research and regulatory contexts.

25 December 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
KBKristian Beran
Kristian Beran
JDJennifer Dressman
Jennifer Dressman
EHEline Hermans
Eline Hermans
René HolmRené Holm
René Holm
KSKia Sepassi
Kia Sepassi
Rat pharmacokinetic studies are commonly utilized in early discovery to support absorption, distribution, metabolism, and excretion optimization of active pharmaceutical ingredients (APIs). The aim of this work was to compare exposures from fit-for-purpose oral suspension and solution formulations in rats to guidance provided by the refined Developability Classification System (rDCS) with respect to identifying potential limits to oral absorption, formulation strategy selection, and to optimize oral bioavailability (BA). This investigation utilized six diverse APIs covering a large range of biorelevant solubility, metabolic stability, and oral BA in rats. While results for our model compounds acetaminophen, voriconazole, fedratinib, lemborexant, and istradefylline indicated oral BA in rats was limited by first-pass metabolism, only the results for voxelotor indicated an oral absorption limitation by intestinal dissolution/solubility. The in vivo studies highlighted challenges and limitations often encountered in early discovery. The rDCS analysis provided a more differentiated assessment of developability risks associated with oral solid dosage form development, incorporating compound-specific physicochemical attributes and human physiology without the need of preclinical data. The rDCS results were shown to align well with the clinical/marketed formulation strategies for the investigated APIs.